Drug Profile
mRNA 4157
Alternative Names: mRNA-4157; mRNA-4157/V940; PCV; Personalized Cancer Vaccine - Moderna TherapeuticsLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Developer Merck Sharp & Dohme; Moderna Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma; Non-small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 12 Mar 2024 Merck Sharp & Dohme and Moderna plan a phase II trial for Bladder cancer (Adjuvant therapy, Combination therapy, First-line therapy) (IM, Injection) in April 2024 (NCT06305767) (EudraCT2023-505658-17)
- 12 Mar 2024 Merck Sharp & Dohme in collaboration with ModernaTX plans a phase II V940-004 trial in Renal cell carcinoma (Adjuvant therapy, Combination therapy) (IM) in April 2024 (NCT06307431) (EudraCT2023-505177-32)
- 29 Feb 2024 Merck in collaboration with Moderna plans a phase II/III INTerpath-007 for Squamous cell cancer (Late-stage disease, Combination therapy, Neoadjuvant therapy) (IV) in April 2024 (NCT06295809) (EudraCT2023-505712-37)